We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Oxford BioDynamics’s Biomarker Predicts ALS Progression
Oxford BioDynamics’s Biomarker Predicts ALS Progression
Oxford BioDynamics’ EpiSwitch blood biomarker assay for amyotrophic lateral sclerosis (ALS) showed which patients were likely to have a fast or slow progressing disease, the company said, citing interim results from a multicenter trial.